Human mesenchymal stromal cells (hMSCs) offer great potential for bone tissue engineering applications, but their in vivo performance remains limited. Pre-conditioning of these cells with small molecules to improve their differentiation prior to implantation or incorporation of growth factors are possible solutions. Insulin-like growth factor-1 (IGF-1) is one of the most abundant growth factors in bone, involved in growth, development and metabolism, but its effects on hMSCs are still subject of debate. Herein, we examined the effects of IGF-1 on proliferation and differentiation of hMSCs in vitro and we found that serum abolished the effects of IGF-1. Only in the absence of serum, IGF-1 increased proliferation, ALP expression and osteogenic gene expression of hMSCs. Furthermore, we examined synergistic effects of BMP-2 and IGF-1 and, although IGF-1 enhanced BMP-2-induced mineralization, IGF-1 only slightly affected in vivo bone formation.
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Introduction
Cell-based bone tissue engineering aims to construct substitutes for large bone defects.
Human mesenchymal stromal cells (hMSCs) are one of the most interesting cell sources for this application, due to their easy isolation, their presence in the adult body and their capacity to proliferate and differentiate. However, so far the in vivo performance of these cells is limited. Studies using human MSCs have resulted in limited amounts of newly formed bone [15] [16] [17] and in order to improve the therapeutic efficacy various strategies have been employed. Researchers have differentiated hMSCs prior to implantation by treating the cells with compounds that induce osteogenic differentiation. It was shown that pre-differentiation with dexamethasone can increase bone formation by hMSCs [17] , whereas other compounds such as trichostatin A [18] and lithium [19] , which did induce osteogenic differentiation, did not affect bone formation in vivo. Thus, so far, better results are obtained by co-implantation of the cells with osteoinductive growth factors such as bone morphogenetic protein-2 (BMP-2) [14] .
Insulin-like-growth-factor-I (IGF-I or somatomedin C) is one of the most abundant growth factors in the bone matrix, involved in growth, development and metabolism. It is produced locally as well as systemically by the liver and its biological actions are regulated by the acidlabile subunit (ALS) and six binding proteins (IGFBPs), which can either enhance or inhibit its actions by preventing access to the IGF-I receptor (IGFR-I) [1] . Systemic production of IGF-1 by the liver is regulated by growth hormone (GH) and this system is thus referred to as 4 4 cancellous bone volume, connectivity and trabecular number and increases trabecular spacing [6] . Interestingly, these mice display a dramatic decrease in mineralization, indicating an essential role for IGF-1 in the development of mature mineralized tissue [6] . IGF-1 null mice have reduced cortical bone size and femur length, although an increase in trabecular bone density and connectivity were also observed [7] . Impaired osteoclastogenesis may explain the latter findings, in line with in vitro studies showing that IGF-1 promotes osteoclastogenesis [7, 8] . Local overexpression of IGF-1 in osteoblasts resulted in increased bone mineral density and trabecular bone volume [9] and, since no increase in osteoblast number was observed, the effects of IGF-1 were suggested to be mediated via enhanced osteoblast function.
Due to its positive effect on osteoblasts, its presence at fracture sites and its involvement in the synthesis of bone matrix [10] , IGF-1 has gained interest as a therapeutic factor in fracture healing; either alone or in combination with other growth factors. In vitro IGF-1 was shown to enhance proliferation of C2C12 cells, osteoblasts [11] , osteoblast-like cells [12] and periodontal ligament fibroblasts [13] . It also induces alkaline phosphatase (ALP) activity, osteocalcin, matrix calcium content, and nodule formation in osteoblasts [14] and has been proven as a chemotactic factor for these cells [15] . Furthermore, in fetal rat calvariae, IGF-1 was shown to enhance osteocalcin secretion and incorporation of proline into collagen type I [16] and to decrease collagen degradation [17] .
In hMSCs, similar effects of IGF-1 on migration were shown [18, 19] , but the effects of IGF-1 on proliferation and differentiation are less clear. Some studies show that IGF-1 does not affect hMSCs at all [20, 21] , whereas on the other hand, MSCs transduced with an IGF-1 adenovirus displayed increased runx2 and collagen type I expression, but not ALP [22] . Also, incorporation of IGF-1 in scaffolds enhanced proliferation and differentiation of attached hMSCs and periodontal ligament fibroblasts [23, 24] . In contrast, it has been reported that IGF-1 stimulates chondrogenic differentiation of hMSCs in the presence of TGF-β [25], which was also demonstrated by adenoviral overexpression of IGF-1 and bone morphogenetic protein-2 (BMP-2) in adipose-derived MSCs [26] . In our own lab, we have shown that treatment of hMSCs with the small molecule db-cAMP enhances in vivo bone formation, which is accompanied by increased secretion of bone specific growth factors, such as BMP-2, but also IGF-1 [27] . Conditioned medium from these treated cells increased proliferation of various cell types, thus indicating a trophic effect [28] , but it is unknown if secreted IGF-1 can affect the implanted hMSCs.
In this study we examined the effects of IGF-1 on proliferation and differentiation of hMSCs, both in the presence and absence of serum, which may contain proteins that neutralize IGF-1 function. In addition, with an adenoviral transduction system, we investigated if IGF-1 has effects on in vivo bone forming capacity of hMSCs, either alone or in combination with BMP-2. 
Materials and methods
Cell culture
Bone marrow aspirates (5-20 ml) were obtained from donors with written informed consent.
hMSCs were isolated and proliferated as described previously [29] . Briefly, aspirates were resuspended using 20 G needles, plated at a density of 5x10 5 cells/cm 2 and cultured in hMSC proliferation medium containing -minimal essential medium (-MEM, Life Technologies), 10% fetal bovine serum (FBS, Cambrex), 0.2 mM ascorbic acid (Asap, Life Technologies), 2 mM L-glutamine (Life Technologies), 100 U/ml penicillin (Life Technologies), 10 g/ml streptomycin (Life Technologies) and 1 ng/ml basic fibroblast growth factor (bFGF, Instruchemie, The Netherlands). Cells were grown at 37°C in a humid atmosphere with 5% CO 2 . Medium was refreshed twice a week and cells were used for further sub-culturing or cryopreservation upon reaching near confluence. For osteogenic experiments, hMSCs were cultured in basic medium, composed of hMSC proliferation medium without bFGF. The osteosarcoma cell line MG-63 was expanded and cultured in basic medium as described above. Recombinant human insulin-like growth factor-I (rhIGF-1) was obtained from R&D systems and used in concentrations between 10 and 150 ng/mL. Recombinant human bone morphogenetic protein-2 (rhBMP-2) was obtained from Biodoor Biotechnology co., Ltd (Hangzhou, China) and used at a concentration of 100 ng/mL, unless stated otherwise. 
Gene expression analysis
Cells were seeded in triplicate in 6-well plates at 10,000 cells/cm 2 in proliferation medium.
The next day, medium was replaced with basic medium with or without serum, and 100 ng/mL IGF-1 was added to denoted conditions. RNA was isolated after 24 hrs, 48 hrs, 72 hrs, 5 days and 10 days, using a Bioke RNA II nucleospin RNA isolation kit (Machery Nagel).
For gene overexpression experiments, cells were kept in culture for 2 or 5 days after medium change and RNA was isolated. RNA concentrations were measured using an ND100 spectrophotometer (Nanodrop technologies, USA) and cDNA was synthesized from 100 ng of a master mix, containing distilled water, forward primer, reverse primer (Sigma Genosys), BSA, and SYBR green I mix (all from Invitrogen) was prepared. Real-time qPCR was performed in a Light-Cycler (Roche). Light-Cycler data were analyzed using the fit points method of Light-Cycler software [30] . The baseline was set at the lower log-linear part above baseline noise and the crossing temperature (C t value) was determined. C t values were normalized to the 18S housekeeping gene and ΔC t (C t, control -C t, sample ) was used to calculate the relative increase in gene expression. Primer sequences are listed in table 1.
Confocal Raman microspectroscopy
UV grade CaF 2 slides for Raman (Crystran LTD, UK) were sterilized using 70% ethanol and subsequently coated with proteins by incubation with FBS for 30 minutes. Then, hMSCs were seeded in triplicate at 5000 cells/cm 2 and allowed to attach overnight in proliferation medium.
The next day, medium was replaced with mineralization medium, with and without IGF-1 (100 ng/mL) and BMP-2 (100 ng/mL). After 28 days of culture, cells were fixed using 10%
formalin and Raman spectra were acquired. A krypton ion laser (Innova 90-K, Coherent Inc.)
emitting at 647.1 nm was used as an excitation source. A 63x/1.0NA water-dipping objective (Zeiss W-plan Apochromat, Carl Zeiss MicroImaging) was used to focus the laser light over the sample and the Raman scattered photons were collected and dispersed on an air-cooled electron-multiplying charge-coupled device (EMCCD: Newton DU-970N, Andor Technology). An excitation power of 35mW on the sample was used. Raman spectra were acquired from 15 randomly chosen cells in each culture condition.
Scanning electron microscopy
Cells were seeded in triplicate in 6-well plates at 5000 cells/cm 2 in proliferation medium. The next day, medium was replaced with basic medium with or without 100 ng/mL IGF-1 and / or 100 ng/mL BMP-2. After 10 and 17 days of culture, cells were fixed using 10% formalin.
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Samples were dehydrated through a graded series of ethanol (70-100%), critical point dried using CO 2 (CPD 030, Balzers) and sputtered with gold (Cressington). SEM images were obtained using a scanning electron microscope (XL30 ESEM, Philips) at an accelerating voltage of 5 or 10 kV.
Adenoviral transductions
Adenovirusses containing an expression vector for IGF-1 (adIGF-1), BMP-2 (adBMP-2) or green fluorescent protein (adGFP, control) were purchased from Biofocus (Leiden, The Netherlands). For adenoviral transductions, hMSCs were seeded at 15,000 cells/cm 2 and allowed to attach overnight. The next day, cells were transduced in basic medium using a previously optimized (data not shown) multiplicity of infection (MOI) of 1000 for adIGF-1 and adGFP and an MOI of 250 for adBMP-2 for 24 hours, after which the medium was replaced with fresh medium. Transduced cells were then used for further in vitro experiments or, in case of the in vivo experiments, trypsinized, and seeded onto ceramic scaffolds for implantation.
Secretion of IGF-1 and BMP-2
hMSCs were seeded and transduced as described above. After the medium change, every 3 days medium was collected and replaced with fresh medium for a total period of 15 (control for in vitro experiments) or 30 (control for in vivo experiment) days. The concentrations of IGF-1 and/or BMP-2 in the medium were determined using ELISA (human IGF-1/BMP-2, Quantikine, R&D systems), according to the manufacturer's protocol.
In vivo bone formation
1-2 mm biphasic calcium phosphate (BCP) particles were prepared and sintered at 1150 0 C as described previously [31] . hMSCs were seeded and transduced as described above. 
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in distilled water, dehydrated through graded alcohol before being cleared in Histoclear for 2 minutes and mounted in Pertex.
Statistics
Data were analyzed in SPSS (PASW statistics) using one-way Anova followed by Tukey's multiple comparison test (P<0.05).
Page 12 of 37 13 13
Results
IGF-1 increases proliferation of hMSCs and MG-63 cells in the absence of serum
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expression of MG-63 cells was significantly decreased with all concentrations of IGF-1, both in FBS-supplemented and FBS-free medium, although in the latter the effect was clearly stronger (supplementary figure 2 and figure 1b) . qPCR on MG-63 cells, using a concentration of 100 ng/mL rhIGF-1, confirmed the effect on ALP gene expression, although at day 10, ALP expression was slightly higher in IGF-1 treated cells. Expression of other osteogenic markers, such as runx2, collagen type I and osteonectin, was also increased by IGF-1 at later timepoints (day 5-10), whereas there was no change in expression of osteocalcin (figure 2b), and S1004A expression was decreased. These data show that IGF-1 increases osteogenic differentiation of both MG-63 cells and hMSCs.
IGF-1 enhances BMP-2-induced mineralization of hMSCs
In mouse knock-out models, IGF-1 was suggested to correlate with matrix formation and therefore we examined the effect of IGF-1 on mineralization of hMSCs. Previously, BMP-2 has been demonstrated to increase mineralization of hMSCs, which was confirmed here for concentrations of 75 and 100 ng/mL (figure 3a), and therefore we also examined synergistic effects between these two growth factors. hMSCs were cultured in mineralization medium supplemented with 75 ng/mL BMP-2, 100 ng/mL IGF-1 or both. After 14 days, neither BMP-2 nor IGF-1 increased calcium deposition, but, compared to control, combined treatment resulted in significant higher amounts of calcium (figure 3b). After 21 days a slight increase in calcium deposition was observed using BMP-2 or IGF-1 alone, but this was not significant.
In contrast, addition of both factors resulted in a synergistic increase in calcium deposition, suggesting an interaction between these two factors. To investigate the mechanism behind the effects of IGF-1, mineralized samples were examined using Raman spectroscopy and scanning electron microscopy (SEM). Figure 3c shows Raman spectra after 28 days of culture. The calcium phosphate peak (961 cm -1 ) observed in cells cultured with BMP-2 and BMP-2/IGF-1 was higher compared to control, but no differences were observed between BMP-2 and BMP-2/IGF-1. Similarly, SEM images showed large amounts of mineralized nodules in both BMP-2 and BMP-2/IGF-1 groups, but we did not find differences in size or frequency of the nodules (figure 3d).
AdIGF-1 increases runx2 and osteonectin expression in vitro
To investigate the effects of secreted IGF-1 on in vitro differentiation of hMSCs, cells were adenovirally transduced with IGF-1 and after 5 days of culture, gene expression levels of runx2, collagen type I, ALP and osteonectin were examined. As depicted in figure 4a , transduction with IGF-1 resulted in high expression levels of IGF-1 already after 2 days.
Compared to control, GFP transduced cells, IGF-1 also increased osteonectin and runx2
expression, but collagen type I levels were not affected and ALP levels were only slightly but not significantly increased after 5 days. The amount of secreted IGF-1 after adenoviral transduction was determined every 3 days for a total period of 15 days, and at the time of qPCR (2 and 5 days), cells secreted approximately 6 or 20 ng/mL IGF-1 respectively (figure 4b).
Co-transduction with adIGF-1 and adBMP-2 enhances BMP-2 secretion and in vivo bone formation
Then, to investigate the effects of IGF-1 and synergistic effects of IGF-1 and BMP-2 on in vivo bone formation, hMSCs were adenovirally transduced with IGF-1 or BMP-2, or both (IGF-1/BMP-2). As a control, cells were transduced with GFP. As a control, cells from the same transduction batch were kept in culture in vitro and the cumulative release profile was determined by collecting medium every 3 days for a total period of 30 days. As depicted in figure 5a , the release of IGF-1 was significantly lower in co-transduced cells but, surprisingly, the secretion of BMP-2 was significantly increased in cells transduced with both BMP-2 and IGF-1, compared to cells transduced with BMP-2 alone. Therefore, to investigate the interplay This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. examined, but these levels were comparable to control (GFP).
In line with these findings, after 6 weeks of implantation, bone formation in the IGF-1/BMP-2 group was higher than in the BMP-2 group (39% and 48% respectively). In contrast, no bone was formed in the GFP group, whereas some scaffolds in the IGF group displayed a low percentage of bone (0.6%) (figure 5c). The in vitro release profile suggests that the increased amounts of bone may be related to enhanced BMP-2 secretion. On the other hand, histological observations showed that bone in the BMP-2/IGF-1 group displayed a lower level of mineralization, indicating a less mature state, compared to BMP-2 or IGF-1 groups. In both BMP-2 and BMP-2/IGF-1 groups, bone marrow was formed inside the scaffolds pores, but the marrow was more densely packed and more granular in the BMP-2/IGF-1 group (arrows, figure 6 ). The less mature state of the bone in the BMP-2/IGF-1 group was confirmed by
Masson's Trichrome staining (figure 7), which showed that only the BMP-2 group contained areas of mature bone (red).
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in the skeleton, such as reduced body weight, growth retardation, diminished mineralization, decreased cortical thickness and reduced cortical bone volume. Although total IGF-1 serum levels were not affected in these models, the amounts of extracellular fluid IGF-1 available to bind to tissue receptors were decreased, thus suggesting that these proteins inhibit IGF-1 activities.
The potential of IGF-1 to improve fracture healing has been demonstrated in in vivo models, but studies are not consistent. Both local and systemic delivery of rhIGF-1 were reported to enhance bone formation in a distraction osteogenesis mouse model [37] , but systemic administration in a rat femoral defect had no effect [38] . Also, systemic delivery increased IGF-1 serum levels, which could potentially result in negative side effects. Therefore, local application using controlled release systems offers a better alternative, especially for tissue engineering applications, but also in this case reports are not consistent. Meinel et al. showed enhanced bone formation by IGF-1-releasing scaffolds [39] , whereas a study by Laffargue et al. shows a slight increase at best [40] . So far, better results are obtained using dual release systems. Implants releasing both IGF-1 and TGF-β resulted in more advanced bone remodeling in fracture models in rats and sheep [41, 42] and the combination of IGF-1 and platelet-derived growth factor (PDGF) also improved bone regeneration [43, 44] . BMP-2 is the main player in stimulating fracture repair, and therefore we investigated the combined treatment/secretion of IGF-1 and BMP-2 [45] . We demonstrate that IGF-1 potentiates BMP-2-induced mineralization in vitro, whereas IGF-1 alone does not affect mineralization, thus showing a synergistic effect. This is in line with a mouse model, which demonstrates that IGF-1 is involved in mineralization [6] . Unexpectedly, using a range of BMP-2 concentrations, mineralization of hMSCs (donor 134A; donor numbers correspond to our internal databank) was increased by 75-100 ng/mL BMP-2, but in a second study (donor 102) using both BMP-2 and IGF-1, a concentration of 75 ng/mL BMP-2 did not significantly affect calcium deposition, although synergistic effects between BMP-2 and IGF-1 were still observed. We speculate that this is a donor-dependent effect.
In addition to these in vitro data, we found higher amounts of newly formed bone by cells co- with increasing concentrations of BMP-2 [46] . Therefore, the increased BMP-2 secretion probably accounts for the increase in bone and bone marrow, however, it is unlikely that the osteoid appearance of the bone is due to higher concentrations of BMP-2, which suggests that IGF-1 has a negative effect on the maturation of bone.
Conclusions
We demonstrated that IGF-1 enhances proliferation and osteogenic differentiation of both hMSCs and MG-63 in vitro, but its effects are highly dependent on the used concentration and This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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the presence of serum. In vivo, IGF-1 had small effects on bone formation of hMSCs, although it seemed to inhibit the maturation of BMP-2-induced bone formation.
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